Cardiology and Heart Failure
Research activity is centered on heart failure with reduced ejection fraction, with attention to patients who may also fall within the broader heart failure with mildly reduced ejection fraction spectrum.
- Heart failure with reduced ejection fraction
- Heart failure with mildly reduced ejection fraction
- Cardiovascular disease
The clinical focus includes treatment strategies relevant to symptomatic cardiac dysfunction and optimization of guideline-based heart failure care.
Neurohormonal and Renal-Metabolic Therapy
The sponsor’s trial activity examines the use of angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter-2 inhibitors in cardiovascular medicine.
- Angiotensin receptor-neprilysin inhibition
- Sodium-glucose cotransporter-2 inhibition
- Renal-metabolic therapy
These areas reflect interest in therapies that influence cardiac loading conditions, neurohormonal signaling, and cardiorenal interactions in heart failure.
Combination Treatment Strategies
Clinical research is directed toward the sequencing and coordination of ARNi and SGLT2i initiation in patients requiring multi-drug heart failure management.
- Therapeutic sequencing
- Concurrent initiation
- Combination pharmacotherapy
The main therapeutic interest is the practical integration of disease-modifying medicines in routine cardiology care.
